访谈优先——研究开始前先提出澄清问题

The skill's workflow requires a clarifying interview before research begins. Here are my questions: **Step 1: Clarifying questions — CAR-T therapy safety in solid tumors** 1. **Safety scope**: Should the report cover the full adverse-event spectrum (CRS, ICANS, on-target/off-tumor toxicity, hematologic toxicity, long-term toxicities), or focus on specific events? 2. **Tumor types**: Any priority solid tumors (e.g., glioblastoma, pancreatic, ovarian, breast), or a pan-solid-tumor overview? 3. **Time frame**: Last 5 years only, or include the full historical record (early-generation trials onward)? 4. **Evidence base**: Clinical trials only (ClinicalTrials.gov + published results), or also include mechanistic/preclinical literature and FDA/EMA regulatory actions? 5. **Output depth**: Concise brief (~1,500 words) or full report (~3,000+ words with HTML)? Please answer any or all — … (Opening + all five questions verbatim from the 2026-09-11 session transcript; ellipsis only shortens the closing.)